BI Cares Financial Contributions Program
BI Cares Financial Contributions Program
Search
Sunshine Act Compliance
Sunshine Act Compliance
Animal Health Innovation
Animal Health Innovation
Moving to Germany
We started in Germany, but we have offices all over the world.
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it is like working on the cutting edge of pharmaceutical development.
Ruminants
Ruminants
Board of Managing Directors
Read more about Boehringer Ingelheim's board of managing directors, with information on all five members and their respective responsibilities.
Phase III EMPA-KIDNEY trial will stop early
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Maria Isabel Rodriguez Fernandez
us-randd-key-fact.pdf
Alexander Guntur
Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US
MERIAL, now part of Boehringer Ingelheim, grows canine vaccine portfolio with the introduction of the RECOMBITEK® Oral Bordetella vaccine.
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
History of our Logo | Corporate Profile | Boehringer Ingelheim US
The logo used by Boehringer Ingelheim today is a stylized depiction of the central section of the imperial palace of Charlemagne.
Life Forward
In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.
Lothar Halmer
Dr. Lothar Halmer is our Chief Quality Officer, and proud to have built a 25-year career with us.